Impact of glaucoma medications on the ocular surface and how ocular surface disease can influence glaucoma treatment
Research output: Contribution to journal › Journal article › Research › peer-review
| Original language | English |
|---|---|
| Journal | Ocular Surface |
| Volume | 29 |
| Pages (from-to) | 456-468 |
| ISSN | 1542-0124 |
| DOIs | |
| Publication status | Published - 2023 |
Bibliographical note
Funding Information:
Tor Paaske Utheim - Co-owner of The Norwegian dry eye clinic and the Clinic of eye health, Oslo, Norway, which delivers talks for and/or receives financial support from: ABIGO, Alcon, Allergan, AMWO, Bausch + Lomb, Bayer, European school for advanced studies in ophthalmology, InnZ Medical, Medilens Nordic, Medistim, Novartis, Santen, Specsavers, Shire Pharmaceuticals, Laboratoire Théa. He has served on the global scientific advisory board for Novartis and Alcon as well as the European advisory board for Shire Pharmaceuticals.
Funding Information:
TFOS expresses its appreciation to Julie Karimi (www.jaka.it), Sabrina Zappia (www.citynetonline.it) and Jeremy Chung Bo Chiang (Sydney, Australia) for their outstanding assistance. TFOS also thanks the following industry partners who supported this TFOS Experts' Meeting with unrestricted donations: Santen, Bausch + Lomb, Dompé, Glaukos, URSAPHARM, Laboratoires Théa and VISUfarma.
ID: 359648365